Summary
Background Adalimumab (ADA) (Humira â , AbbVie Inc., U.S.A.) is approved by the European Medicines Agency for children aged ≥ 4 years with severe plaque psoriasis.
Objectives To evaluate the long-term efficacy and safety of ADA in children with severe plaque psoriasis.
Methods Results are presented from the 52-week long-term extension (LTE) of the randomized, double-blind, double-dummy, phase III trial, in children with severe plaque psoriasis (results from prior periods have been published). Patients aged ≥ 4 and < 18 years were randomized 1 : 1 : 1 to ADA 0Á8 mg kg À1 (40 mg maximum) or 0Á4 mg kg À1 (20 mg maximum) every other week or to methotrexate (MTX) 0Á1-0Á4 mg kg À1 (25 mg maximum) weekly. The 16-week initial treatment (IT) period was followed by a 36-week withdrawal period and a 16-week retreatment period. Patients could enter the LTE at prespecified time points to receive ADA 0Á8 mg kg À1 (blinded or open label) or ADA 0Á4 mg kg À1 (blinded), or to remain off treatment. Efficacy is reported for patient groups according to doses received in the IT and LTE periods.
Results Of the 114 patients randomized in the IT period, 108 entered the LTE (n = 36 in each group); 93 received ADA 0Á8 mg kg À1 . Efficacy (≥ 75% improvement from baseline in Psoriasis Area and Severity Index) was maintained or improved from entry to the end of the LTE: MTX(IT)/ADA 0Á8(LTE) 31-86% of patients; ADA 0Á4(IT)/0Á4 or 0Á8(LTE) 28-47%; ADA 0Á8(IT)/0Á8(LTE) 50-72%. No serious infections occurred in the LTE.
Conclusions After 52 weeks of long-term ADA treatment in children aged 4-18 years with severe plaque psoriasis, disease severity was reduced and maintained or further improved, as demonstrated by efficacy outcomes. No new safety risks were identified.
What's already known about this topic?
• The results from the first three periods of this phase III trial in children aged [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] years with severe plaque psoriasis suggest that adalimumab is a safe and efficacious treatment option in this population.
What does this study add?
• This is the first study to evaluate long-term treatment of adalimumab in children with severe psoriasis, and the first to evaluate switching from methotrexate to adalimumab in this population.
Plaque psoriasis is a chronic inflammatory skin disease. Its overall prevalence for children 0-18 years of age is 0Á2-1Á4% in Europe and approximately 1% in the U.S.A. 1, 2 The disease in children and adults is associated with impaired quality of life [3] [4] [5] and an increased risk of comorbidities, including obesity, metabolic syndrome, cardiovascular risk, autoimmune diseases [6] [7] [8] and psychosocial issues, especially depression. [9] [10] [11] The limited number of approved systemic therapies and randomized controlled trials evaluating treatment in children has challenged the effective management of the disease. Conventional treatment options include topical therapy for mildto-moderate disease, 12 and for severe or refractory disease, ultraviolet (UV)B phototherapy, narrowband UVB therapy if accessible and systemic treatments, including methotrexate (MTX), ciclosporin, acitretin (retinoids) and biologics. [13] [14] [15] Approved biologic therapies for plaque psoriasis in children include the tumour necrosis factor (TNF)-a inhibitors etanercept [16] [17] [18] [19] and adalimumab (ADA), 20 and the p40 inhibitor ustekinumab. 18, 19 Etanercept is approved by the European Medicines Agency (EMA) for children aged ≥ 6 years with severe disease, and by the U.S. Food and Drug Administration (FDA) for children aged ≥ 4 years; ADA is approved by the EMA for children aged ≥ 4 years with severe chronic disease; and ustekinumab is approved by the EMA and FDA for children aged ≥ 12 years with moderate-to-severe disease.
Results of long-term treatment of children with moderate-tosevere psoriasis have been published for open-label etanercept, 21, 22 and for ustekinumab vs. placebo. 23 Biologic treatment of psoriasis in children is reported as less likely to result in adverse events or in treatment discontinuation compared with MTX. 24 The current analysis reports results from the first randomized 52-week controlled trial, comparing the efficacy and safety of a biologic treatment, ADA (Humira â , AbbVie Inc., North Chicago, IL, U.S.A.), a recombinant fully human monoclonal antibody directed against TNF-a, with the active comparator MTX, in children with severe plaque psoriasis. Results from the first three periods of this trial have been reported. 25 Patients and methods
Participants
Patients were children aged ≥ 4 and < 18 years with a body weight of ≥ 15 kg and severe plaque psoriasis for ≥ 6 months, who had failed to respond to topical therapy. Severe psoriasis was defined as meeting at least one of the following criteria: (i) Other LTE evaluations included the CDLQI and the Pediatric Quality of Life Inventory. Absolute PASI values at score categories ≤ 5 and ≤ 3 were analysed post hoc across the IT period and the LTE. Safety was evaluated by treatment-emergent adverse events. Efficacy and safety were also evaluated for the subgroup of patients who failed MTX treatment in the IT period and were switched to ADA 0Á8 mg kg À1 in the LTE.
Statistical analysis
Efficacy was evaluated for all randomized patients (intentionto-treat population) in the IT period (n = 114); the statistical analysis and results have been reported previously. 25 In the LTE, the intention-to-treat population included all patients who entered the LTE (n = 108). Missing data were imputed using nonresponder imputation for dichotomous efficacy end points and last observation carried forward for continuous end points. The safety population consisted of all who received at least one dose of study medication in the trial. As the majority (92Á6%, 100 of 108) of patients received ADA during the LTE, no statistical comparisons among efficacy groups were performed in the LTE.
Results
Of the 114 initially randomized patients (MTX, n = 37; ADA 0Á4 mg kg À1 , n = 39; ADA 0Á8 mg kg À1 , n = 38), 108 entered the LTE (n = 36 in each efficacy group) (Fig. 2) .
Patients who entered the LTE according to prespecified entry criteria included eight who escaped the IT period early (n = 6 at week 4 and n = 2 at week 8), 51 who were nonresponders at the end of the IT period, 15 who completed the IT period and did not lose disease control at the end of the treatment withdrawal period, and 34 who completed the IT period, lost disease control in the withdrawal period and completed the retreatment period. (Fig. 2) . Eight of the 15 patients who did not lose disease control in the withdrawal period and who continued off treatment in the LTE remained off drug in the LTE, and seven of 15 lost disease control in the LTE and were re-treated with the same blinded dose they received in the IT period (or with ADA 0Á8 mg kg À1 for those initially randomized to MTX in the IT period); this included three who were re-treated in the LTE with ADA 0Á4 mg kg À1 and four who were re-treated with ADA 0Á8 mg kg À1 . Responders or nonresponders were patients who achieved or did not achieve ≥ 75% improvement in Psoriasis Area and Severity Index and a Physician's Global Assessment (PGA) score of 0 or 1 at the end of the initial treatment (IT) period.
e Patients who lost disease control in the long-term extension (LTE) could receive ADA until the end of the LTE at the initial randomized dose, or ADA 0Á8 mg kg À1 if the initial randomized drug was MTX.
Patients entering the withdrawal period initially randomized to MTX received blinded ADA 0Á8 mg kg À1 in the retreatment period and the LTE.
Patients initially randomized to ADA 0Á4 mg kg À1 or 0Á8 mg kg À1 received blinded ADA in the retreatment period and the LTE based on their initial randomized dose. All patients had a dose-increase option to open-label ADA 0Á8 mg kg À1 in the LTE.
In total 18 of 108 patients (16Á7%) discontinued the LTE; the primary reason was lack of efficacy (n = 10). The median exposure to any ADA dose was 364 days (range 42-380) during the LTE (n = 100), and 392 days (range 21-611) during the entire study (n = 111). The baseline demographics and disease characteristics were balanced among the IT-period dose groups. 25 The most commonly reported concomitant topical medications were salicylic acid (6%) and emollients and protectives (5Á3%). At baseline, the mean AE SD patient body weight (51Á3 AE 20Á3 kg) and body mass index (BMI) (21Á1 AE 4Á9 kg m À2 )
were balanced across baseline treatment groups (MTX, ADA 0Á4 mg, ADA 0Á8 mg). The numbers of patients in each BMI category (based on age-and sex-specific World Health Organization BMI charts) were 68 of 114 (59Á6%) normal weight, 17 (14Á9%) overweight and 24 (21Á1%) obese; the percentages of patients within each category were also balanced across baseline treatment groups. 25 There were no trends regarding the percentages of patients achieving PASI 75 across the BMI categories of normal weight, overweight and obese: MTX(IT)/ADA 0Á8(LTE), 90%, 100%, 63% (n = 21, 6, 8, respectively); ADA 0Á4(IT)/ADA 0Á4 or 0Á8(LTE), 48%, 50%, 50% (n = 23, 4, 8, respectively); ADA 0Á8(IT)/ADA 0Á8(LTE), 75%, 57%, 83% (n = 20, 7, 6, respectively). The small numbers of patients in each of the overweight and obese categories limit any interpretation of these results.
Efficacy
Treatment response, measured by achievement of PASI 75, PASI 90 and PASI 100, improved for all efficacy groups from the start of the LTE across 52 weeks of treatment (Fig. 3) . At LTE week 52, PASI 75, 90 and 100 response rates for each efficacy group were higher than the corresponding rates at week 16 of the IT period. Response measured by achievement of PGA 0/1 also improved for all efficacy groups from the start of the LTE across 52 weeks of treatment, and rates at LTE week 52 for the MTX(IT)/ADA 0Á8(LTE) and ADA 0Á4(IT)/ 0Á4 or 0Á8(LTE) groups were higher than the corresponding rates at week 16 of the IT period (Fig. 4) . Patients in the MTX(IT)/ADA 0Á8(LTE) group had a higher response rate at LTE week 52 than those in the other two efficacy groups for all efficacy measures (Figs. 3 and 4) .
Treatment response measured by absolute PASI ≤ 3 and ≤ 5 also improved for all three efficacy groups from the start of the LTE across 52 weeks of treatment, and the rates at week 52 for each efficacy group were higher than the corresponding rates at week 16 of the IT period, except for PASI ≤ 5 for the ADA 0Á4(IT)/0Á4 or 0Á8(LTE) groups (Fig. 5) .
Patients unresponsive to MTX in the IT period who at the end of that period were transitioned directly to the LTE to receive open-label ADA 0Á8 mg kg À1 experienced improved treatment response as measured by PASI 75 and PASI 90 as early as 4 weeks after switching to ADA, and generally , and at IT weeks 8 and 11 for MTX. Statistically significant at ***P = 0Á001, **P = 0Á01, *P = 0Á05 levels for MTX vs. ADA 0Á4 mg kg À1 or MTX vs. ADA 0Á8 mg kg À1 dosage in the IT period. Efficacy groups in the long-term extension (LTE) are defined based on the initial randomization assignment in the IT period and on the dose received in the LTE.
maintained the respective level of response through the rest of the LTE (Fig. 6a) . The PASI 100 response rate for these patients also improved starting at LTE week 4, and continued to improve to the end of the period (Fig. 6a) . The PGA 0/1 response rate improved from weeks 1 to 11 and then slightly decreased by the end of the period (Fig. 6b) . Improvements in quality-of-life scores during the LTE were highest for patients initially randomized to ADA 0Á8 mg kg À1 . For all efficacy groups, quality-of-life scores at the end of the IT period, as measured by CDLQI and Pediatric Quality of Life Inventory, improved across the 52 weeks of the LTE (Table 1) .
Safety
During the LTE, there were 407Á4 adverse events per 100 patient-years (PYs) ( Table 2 ). The most frequently reported events (≥ 20% of patients) were nasopharyngitis and headache. Injection-site reactions occurred in 3Á7% of patients (four of 108). There were no malignancies.
Five serious adverse events occurred during the LTE (five of 108, 4Á6% overall) ( Table 2 ). Eight patients (eight of 108, 7Á4%) reported severe adverse events, one of whom discontinued the study drug (Table 2) . One patient had a moderate event of herpes zoster in the LTE that the investigator considered to be possibly related to ADA. Overall, a higher rate of events related to allergic reactions (urticaria, pruritus, bronchospasm and asthma) was seen for patients initially randomized to MTX (18Á2 events per 100 PYs) than for patients initially randomized to ADA (4Á5 events per 100 PYs); there were no serious events related to allergic reaction.
For patients who failed MTX at week 16 of the IT period (n = 19), the rate of adverse events during the LTE was 381Á5 per 100 PYs for any event, 5Á7 per 100 PYs for serious events, 142Á2 per 100 PYs for infections and 56Á9 per 100 PYs for events at least possibly related to ADA.
There were no serious infections. Infections included upper respiratory tract infection (n = 5), nasopharyngitis (n = 4), rhinitis (n = 2), influenza (n = 2), pharyngitis (n = 2), bronchitis (n = 2), oral herpes (n = 1), gastroenteritis (n = 1), otitis media (n = 1) and urinary tract infection (n = 1).
Discussion
Treatment of children with severe chronic psoriasis remains a challenge. Standardized treatment guidelines are lacking and the evidence for the efficacy and safety of systemic treatments in paediatric psoriasis is limited. The treatment approach is based on systemic treatments for adults, even though most of these drugs are not approved for paediatric use. 26 While MTX was first investigated in this clinical trial, only retrospective case series are available for drugs such as ciclosporin and acitretin. [26] [27] [28] The chronicity of psoriasis and its negative effect on patient quality of life can necessitate long-term treatment, thus the efficacy and safety of long-term systemic therapy are important in this population. However, they have been evaluated in only a few clinical trials, which show the strongest evidence for biologics. [21] [22] [23] 29 Methotrexate is approved for adult plaque psoriasis only, but up to now has been the first-line systemic agent recommended for paediatric psoriasis.
14 Biologics have significantly changed psoriasis treatment over the decades and have greatly improved patients' health-related quality of life and patient-relevant outcomes. [30] [31] [32] [33] ADA has been used to treat adults with moderate-to-severe plaque psoriasis for over a decade, and has shown superior efficacy to systemic treatments, such as MTX. Its accumulating safety data resulted in a first-line label for adults and children. 34, 35 By blocking TNF-a, ADA inhibits inflammation in psoriatic lesions by decreasing the level of proinflammatory cytokines. Other are defined based on the initial randomization assignment in the IT period, and on the dose received in the LTE.
biologics approved for the treatment of children with plaque psoriasis are etanercept (age ≥ 6 years with severe disease) and ustekinumab (age ≥ 12 years with moderate-to-severe disease).
In this active-comparator-controlled study, response at the end of the initial 16 weeks to ADA 0Á8 mg kg À1 was maintained through the 52-week LTE period of this trial. These results in children with severe psoriasis are consistent with results from ADA clinical trials in adults with moderate-tosevere psoriasis. In an analysis of 250 adults, PASI 75, 90 and 100 rates after 160 weeks of ADA treatment were 76%, 50% and 31%, respectively, 36 compared with 68Á5%, 48Á1%
and 29Á6% of children overall in the current study. In an interim analysis from a 10-year observational registry of ADA treatment in adults (n = 6059), PGA 0/1 was achieved between 3 and 5 years of treatment by > 60% of adults, compared with 60Á2% of children overall in the current study. 37 Similar results have also been reported in trials of other biologic therapies approved for moderate-to-severe psoriasis in children. A 5-year open-label extension study of etanercept confirmed its efficacy (70%, 40% and 50% achievement rates for PASI 75, PASI 90 and PGA 0/1) following long-term treatment, with no new safety concerns. 21 In a 52-week randomized, placebo-controlled trial, response rates for the standard ustekinumab dose were generally maintained from week 12 through 1 year (PASI 75, 80Á6%; PASI 90, 61Á1%; PGA 0/1, 69Á4%), with no unexpected adverse events. 23 Using absolute PASI as a treatment goal may provide more objective clinical information about the efficacy of a treatment, as it reflects the improvement of a patient's disease severity independently from the baseline value. The achievement rate of each absolute PASI cut-off (≤ 5 and ≤ 3) in this study was numerically higher at week 52 of the LTE than at LTE entry, for each LTE efficacy group, and thus may represent a treatment goal achievement of minor disease symptoms.
Patients with psoriasis onset at a young age are likely to have more depression, sleep problems and social discrimination, and a higher lifetime Dermatology Life Quality Index, 38, 39 even more so with severe psoriasis. Physical, psychological and social impairments might have a significant impact on the development of these patients and might result in an inability to achieve 'full-life potential' (also termed cumulative life course impairment) early in their lives. 40 Therefore, there is still an unmet medical need to provide long-term effective and safe psoriasis therapy to patients at a young age in order to control disease chronicity and limit its consequences on patient quality of life. The results from this first comparative study showed that at the initial 16 weeks, patients' quality of life improved in relation to their clinical response, and was maintained throughout the 52-week period.
Patients initially randomized to ADA 0Á8 mg kg À1 showed the greatest mean improvement in quality-of-life scores during the LTE compared with the other groups. For the subgroup who did not respond to MTX treatment in the IT period and continued directly to open-label treatment with ADA 0Á8 mg kg À1 in the LTE, the majority achieved PASI 75, PASI 90 and PGA 0/1 (80%) response throughout the LTE, starting as early as week 4. This improvement after switching is consistent with results of other trials in adults with moderateto-severe psoriasis. In an open-label trial, 61% of patients (n = 41) who had failed prior treatment with MTX achieved PGA 0/ 1 after 16 weeks of ADA. 41 In an open-label randomized controlled trial, patients who switched from initial treatment with MTX (n = 215) to infliximab (n = 63) had a higher response rate at week 26 than patients who did not switch (73% vs. 30Á7% achieved PASI 75, and 75% vs. 28% achieved PGA 0/ 1). 42 In a real-world practice study, patients (n = 267) improved their skin response following a switch to biologics after treatment with conventional systemic agents. In that study the mean time to first follow-up after switching was 6 weeks, and the mean AE SD PASI scores before and after switching were 13Á6 AE 8Á8 and 5Á7 AE 5Á8, respectively. 43 In the current study, following ADA 0Á8 mg kg À1 treatment in the LTE, the MTX responders in the IT period had a generally greater treatment response rate across efficacy outcomes than MTX nonresponders in the IT period. Possible reasons include lack of a washout period for nonresponders, or more patients who escaped early in the IT period entering the LTE. In general, the response rates for both groups were greater than the rates in the LTE for patients who received ADA in the IT period and in the LTE. The ADA safety profile across all efficacy groups during the 52-week LTE was similar to the 16-week IT period profile, 25 including low numbers of serious adverse events, severe adverse events, injection-site reactions and allergic reactions, and was therefore consistent with the known safety profile of ADA in adults with psoriasis. No serious infections were observed during the LTE. Rates for adverse events leading to discontinuation, allergic reactions or injection-site reactions were low. The most common adverse events were nasopharyngitis and upper respiratory tract infections. Similar safety results were seen in the long-term etanercept (n = 182) and ustekinumab (n = 110) trials in children with moderate-to-severe psoriasis, 21, 23 including the rate of the more common adverse events of nasopharyngitis (25Á9% ADA, 26Á0% etanercept) and upper respiratory tract infection (12Á0% ADA, 12Á7% ustekinumab). Low rates were observed (ADA, etanercept and ustekinumab, respectively) for serious adverse events (4Á6%, 3Á8% and 4Á5%), serious infections (0%, 1Á1% and 1Á8%), tuberculosis (1Á9%, not reported and 0%) and injection-site reactions (3Á7%, 8Á8% and 0Á9%). No malignancies or opportunistic infections were observed in any of these long-term trials. The long-term safety profile of ADA from this study is also supported by the safety profiles from other trials of long-term ADA treatment of adults and children with psoriasis and other indications (rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn disease). The adverse events observed in these trials and analyses are similar to those experienced by the current paediatric Included patients who received at least one dose of study drug during the trial.
b Included angio-oedema, anaphylaxis, lupus-like reactions and systemic lupus erythematosus. population. [35] [36] [37] 44, 45 The rates of events per 100 PYs were similar across these trials and analyses. The adverse event rate for IT MTX responders who received ADA 0Á8 mg kg À1 in the LTE was similar to the rates for patients receiving ADA in the other study periods. A limitation of this study is the relatively small number of patients in each efficacy group during the LTE, which makes definitive conclusions difficult.
In conclusion, this study demonstrated that the efficacy of ADA 0Á8 mg kg À1 dosed every other week was maintained through 52 weeks of treatment for this population of children with severe plaque psoriasis. For patients unresponsive to MTX after 16 weeks, treatment response improved after switching to open-label ADA 0Á8 mg kg À1 every other week, and was generally maintained during 52 weeks of treatment in the extension period. No new safety risks were identified. These findings support the use of ADA as a long-term treatment option for children with severe plaque psoriasis.
